Back

Personalised risk stratification in cardiomyopathies: where are we now? - discussion

30 August 2026 (18:15 - 18:30)
Organised by: Logo
Congress Presentation Part of: Personalised risk stratification in cardiomyopathies: where are we now? Risk Factors and Risk Assessment ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

3 More presentations in this session

Presentation thumbnail
What is the current role of cardiac magnetic resonance and clinical risk scores in risk stratification for hypertrophic cardiomyopathy?
Professor P. Elliott (London, GB)
Slides Video
Presentation thumbnail
Is the arrhythmogenic right ventricular cardiomyopathy phenotype outdated for risk prediction?
Doctor A. te Riele (Utrecht, NL)
Slides Video
Presentation thumbnail
Genotype or phenotype or both? Current risk prediction in dilated cardiomyopathy and non-dilated left ventricular cardiomyopathy
Associate Professor L. Crotti (Milan, IT)
Slides Video

Access the full session

Session thumbnail
Personalised risk stratification in cardiomyopathies: where are we now?
Video

The Event

Event poster

ESC Congress 2026

30 August 2026 18:15 CET
You may be interested in
thumbnail
Congress Session
Risk stratification of sudden cardiac death in cardiomyopathies
26 August 2023
thumbnail
Congress Presentation
Do the variables that the clinical cardiologist looks at when requesting a genetic study in the study of idiopathic dilated cardiomyopathy have predictive value?
29 June 2021
thumbnail
Webinar
New concepts in dilated and non-dilated LV cardiomyopathies. ESC 2023 Clinical Practice Guidelines - Webinar Series
18 October 2023
thumbnail
Webinar
The essential skill in cardio-oncology: baseline cardiotoxicity risk stratification
8 March 2021

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources